Navigation Links
Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM)
Date:6/4/2009

EXTON, Pa., June 4 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the baseline LaunchTrends(TM): SIMPONI report. The survey was completed by U.S. Rheumatologists in May 2009, just days after the FDA announced approval for SIMPONI (golimumab).

Once monthly dosing seems to be playing well, according to the Rheumatologists in the study who anticipate relatively quick uptake of SIMPONI. 84% of the Rheumatologists surveyed report that they intend to use SIMPONI within the next six months, and a fair proportion intend to incorporate SIMPONI into their armamentarium right away. The majority of RA patients likely to be placed on SIMPONI are expected to be switched from current biologic agents, primarily impacting use of Enbrel, Humira and Remicade. The main advantages that clinicians perceive for SIMPONI compared to currently available agents are the monthly dosing regimen and self injection. On the downside, SIMPONI is a new addition to an already crowded market of TNF agents with a similar mechanism of action and a lack of any clear clinical differentiation. Concern was also expressed about the lack of radiographic data at the time of launch to support the drug's ability to slow the progression of disease.

Adding to the competitive environment, the FDA approved UCB's CIMZIA(R) (certolizumab) for Rheumatoid Arthritis on May 14th, bringing yet another once monthly TNF agent into the mix. In addition to the recent launches of SIMPONI and CIMZIA there is significant interest among Rheumatologists in Roche's ACTEMRA(R) (tocilizumab), an IL-6 blocker currently under review with the FDA. When presented with all three products, interest was highest for ACTEMRA.

LaunchTrends(TM) measures launch effectiveness of new products from FDA approval through six months post launch. The next wave of this report, measuring uptake at one month post launch, will be fielded on June 22 and will be expanded to include CIMZIA in the competitive set. The results will be published in mid-July.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends' syndicated publications, please contact Paul Callahan at (610) 363-3872 or visit us at www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex, Inc. Announces Monthly Investor Conference Call
2. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. National Council on Disability Monthly Bulletin for February, 2009
4. U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6
5. Medical City Hospital Named by Texas Monthly as One of the Top Ten Best Companies to Work for in Texas
6. National Council on Disability Monthly Bulletin for November 2008
7. Renowned Thoracic Surgeon Recognized as Top Doctor by Peers in Annual New Jersey Monthly Magazine Survey
8. National Council on Disability Monthly Bulletin for October 2008
9. National Council on Disability Monthly Bulletin for June, 2008
10. National Council on Disability Monthly Bulletin for March 2008
11. National Council on Disability Monthly Bulletin for February, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today ... Inc.,s Supplier Horizon Award . One ... Guerbet was recognized for its support of Premier members ... through clinical excellence, and commitment to lower costs. ... receive this recognition of our outstanding customer service from ...
Breaking Medicine Technology: